MONKEYPOX (MPOX) DIAGNOSIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Monkeypox (Mpox) Diagnosis Market, By Test Type (Polymerase Chain Reaction (PCR) Tests, Serological Tests, Antigen Detection Tests, and Viral Culture Tests), By Mode (Laboratory Testing and Point of Care Testing), By Component (Hardware and Software), By End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On October 3, 2024, the World Health Organization (WHO) approved the first mpox diagnostic test for emergency use, the Alinity m MPXV assay by Abbott Molecular. This real-time polymerase chain reaction test detects monkeypox virus DNA from skin lesion swabs, aiding quick and accurate diagnoses. The approval addresses limited testing capacity in regions like Africa, where outbreaks persist.
On August 23, 2024, Erba Transasia, an India-based company specializing in diagnostic solutions, launched the ErbaMDx MonkeyPox RT-polymerase chain reaction Kit, India’s first indigenously manufactured monkeypox polymerase chain reaction test. Validated by ICMR, Indian Council of Medical Research and approved by CDSCO, Central Drugs Standard Control Organization, the kit offers 97.5% sensitivity and 100% specificity, with results in under an hour. It’s cost-effective, suitable for regions with limited cold chain infrastructure, and can be used with existing COVID-19 polymerase chain reaction systems.
On April 10, 2024, Labcorp, a global life sciences and healthcare company, received U.S. Food and Drug Administration (FDA) emergency use authorization for its Mpox polymerase chain reaction Test Home Collection Kit, the first at-home test for Monkeypox. The kit allows patients to collect samples privately, with results sent to physicians for diagnosis and treatment.